Atea Pharmaceuticals, Inc. (AVIR)
After hours:
| Previous close | 3.6100 |
| Open | 3.6200 |
| Bid | 3.6500 x 200 |
| Ask | 3.6800 x 200 |
| Day's range | 3.6200 - 3.7050 |
| 52-week range | 2.7650 - 4.6000 |
| Volume | |
| Avg. volume | 290,495 |
| Market cap | 309.099M |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9500 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
GlobeNewswireAtea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Wednesday, June 5, 2024 at 10:30 a.m. ET in New York. A live webcast of the presentation will be
- GlobeNewswire
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases,
- GuruFocus.com
Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
Discover key updates on Atea's financial health, clinical advancements, and strategic outlook as they pave the way through 2024.
